GZD856 formic

GZD856 formic is a potent, orally bioavailable small molecule inhibitor targeting PDGFRα/β and Bcr-Abl, including the resistant T315I mutant. It demonstrates significant antitumor efficacy in preclinical models, making it a valuable research tool for studying tyrosine kinase-driven cancers in both in vitro and in vivo settings.